Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab

INTRODUCTION: IL-13 is the primary upregulated cytokine in atopic dermatitis (AD) skin and is the pathogenic mediator driving AD pathophysiology. Lebrikizumab, tralokinumab and cendakimab are therapeutic monoclonal antibodies (mAb) that target IL-13. METHODS: We undertook studies to compare in vitro...

Descripción completa

Detalles Bibliográficos
Autores principales: Okragly, Angela J., Ryuzoji, Aya, Wulur, Isabella, Daniels, Montanea, Van Horn, Robert D., Patel, Chetan N., Benschop, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307934/
https://www.ncbi.nlm.nih.gov/pubmed/37310643
http://dx.doi.org/10.1007/s13555-023-00947-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307934/
https://www.ncbi.nlm.nih.gov/pubmed/37310643
http://dx.doi.org/10.1007/s13555-023-00947-7

Ejemplares similares